Chapter

In October 2022, the Society for Immunotherapy of Cancer released a checklist for running phase 3 cancer immunotherapy combination studies. SITC's aim with these guidelines is to maximize the value of these trials. In this episode, Fierce Pharma staff writer Angus Liu discusses the checklist with Dr. Michael Atkins, the first author.

To learn more about topics in this episode:
Moderna checks a few boxes in phase 3 mRNA flu shot trial, but misses on B strains and safety
BD issues cybersecurity alert for hacking risk found in Alaris infusion pump software
Apellis wins FDA approval for first geographic atrophy drug
With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

In October 2022, the Society for Immunotherapy of Cancer released a checklist for running phase 3 cancer immunotherapy combination studies. SITC's aim with these guidelines is to maximize the value of these trials. In this episode, Fierce Pharma staff writer Angus Liu discusses the checklist with Dr. Michael Atkins, the first author.
To learn more about topics in this episode:
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/moderna-checks-few-boxes-phase-3-flu-shot-trial-misses-b-strains-and-safety">Moderna checks a few boxes in phase 3 mRNA flu shot trial, but misses on B strains and safety</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/bd-issues-cybersecurity-alert-hacking-risk-found-alaris-infusion-pump-software">BD issues cybersecurity alert for hacking risk found in Alaris infusion pump software</a></li>
<li><a href="https://www.fiercepharma.com/pharma/apellis-wins-fda-approval-first-geographic-atrophy-drug">Apellis wins FDA approval for first geographic atrophy drug</a></li>
<li><a href="https://www.fiercepharma.com/marketing/travere-fda-approval-bristol-myers-castoff-unique-drug-rare-kidney-disease">With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement